At the same time, studies have shown that 18F-DCFPyL PET/CT imaging has a lower false positive rate in diagnosing bone metastasis in prostate cancer, especially in the ribs, scapula, and clavicle, compared with the more widely used 18F-PSMA-1007 in clinical practice (10). This evidence concerns the gene FOLH1 and prostate cancer.